TrialJapanese journal of clinical oncology2025

Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer.

Satoshi Kano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.